Cargando…
The Current Landscape for METex14 Skipping Mutations in Non–Small Cell Lung Cancer
Capmatinib and tepotinib received US Food and Drug Administration (FDA) approval for mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping alteration in 2020 and 2021, respectively. Capmatinib was FDA approved in May 2020 under accelerated approval for the treatment of patients with met...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9328457/ https://www.ncbi.nlm.nih.gov/pubmed/35910499 http://dx.doi.org/10.6004/jadpro.2022.13.5.8 |